Key feature of psoriasis | Corticosteroid | Vitamin D analogue | Cal/BD foam fixed-dose combinationa | Topical calcineurin inhibitor | Salicylic acid | Urea | Tarb |
---|---|---|---|---|---|---|---|
Redness | +++ | +/++ | +++ | +/++c | 0 | 0 | + |
Scaling | + | +/++d | ++ | 0 | +++ | ++ | + |
Thickness or infiltration | ++ | +/++ | +++ | + | 0 | 0 | ++ |
Itching | ++/+++ | 0 | +++ | ++ | 0 | + | ++ |
Symbols represent clinical effectiveness, where + = somewhat effective and +++ = very effective; 0 represents no or minimal impact on the symptom. This information is based on the expert opinion and clinical experience of the authors and provides a suggested option for a given clinical scenario to contribute to an informed decision; it does not advise that a given treatment is warranted. Only the most commonly used vehicles are included in the Table. It is not intended as a comprehensive list. Clinical effectiveness is based on the active ingredients; overall effectiveness in the real world is also driven by patient adherence and the vehicle plays an important part in patient behaviour. aCal/BD is marketed by LEO Pharma, the sponsor of this work, under the tradenames (UK) Enstilar (Cal/BD foam) and Dovobet (Cal/BD gel and ointment). bUse of tar is country-specific: coal-tar preparations are used in the UK32 and elsewhere as part of the Goeckermann regimen33; however, tar is rarely used in Switzerland, Austria, or Scandinavia. c++ = when used on face. dCream = +; ointment = ++.